Australia’s biggest science investment fund has another $210 million for medical research startups

Australian VC firm, Brandon Capital Partners, has just raised another $210 million to invest in commercialising medical research, and is already on the hunt for another $250 million as it edges towards $1 billion in science investments.

The 5th Medical Research Commercialisation Fund, MRCF5, raised AU$210 million from existing investors, taking the total in the life sciences fund to  more than AU$700m. Brandon Capital Managing Director, Dr Chris Nave, who’s also MRCF CEO, says they’re now looking at approaching selected institutional investors about the potential for a second close to raise an additional AU$250m.

Brandon has built a solid track record of medical investments in just 11 years, investing in more than 40 companies and recently exiting from three: Elastagen, sold to Allergan last year, Spinifex (sold to Novartis in 2015) and Fibrotech (sold to Shire in 2014).

<img aria-describedby="caption-attachment-74957" class="size-medium wp-image-74957" src="" alt="" width="184" height="200" srcset=" 184w,

Read Full Content Here […]